Suven Pharma
Ticker > Company >

Suven Pharma share price

Suven Pharmaceuticals Ltd.

NSE: SUVENPHAR BSE: 543064 SECTOR: Pharmaceuticals & Drugs  69k   298   44

1224.25
-1.35 (-0.11%)
BSE: 21 Feb 04:01 PM

Price Summary

Today's High

₹ 1230

Today's Low

₹ 1177.2

52 Week High

₹ 1359

52 Week Low

₹ 597

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 31165.11 Cr.

Enterprise Value

₹ 31182.11 Cr.

No. of Shares

25.46 Cr.

P/E

110.83

P/B

13.59

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  90.05

CASH

₹ 21.58 Cr.

DEBT

₹ 38.58 Cr.

Promoter Holding

50.1 %

EPS (TTM)

₹  11.05

Sales Growth

-22.94%

ROE

16.03 %

ROCE

21.27%

Profit Growth

-29.54 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 20 Indices.

NFT500MOM50

Nifty500 Momentum 50
47480.2
  -809.850000000006 (-1.67705355451072%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
43445.95
  -603.950000000004 (-1.37105873112086%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
41334.35
  -247.650000000001 (-0.595570198643647%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
38119.5
  -615.949999999997 (-1.59014546106989%)

NFT500MOQ50

Nifty500 Multicap Momentum Quality 50 index
37247.15
  -402 (-1.06775318964705%)

NIFTY500

Nifty 500
20690.25
  -140.849999999999 (-0.676152483546233%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17241.7
  -159 (-0.913756343135619%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
15600.15
  -118.15 (-0.751671618432015%)

NIFTYSMALLCAP250

Nifty Smallcap 250
14683.4
  -83.8999999999996 (-0.568147190075363%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14254.25
  -101.700000000001 (-0.708417067487699%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
13392.8
  -155.400000000001 (-1.14701583974256%)

NFT500EQUAL

Nifty 500 Equal Weight
12369.5
  -82.1499999999996 (-0.659751920428209%)

NIFTYTOTALMCAP

Nifty Total Market index
11634.25
  -78.5 (-0.670209814091483%)

SMLCAP

S&P Bse Small Cap
45856
  -198.940000000002 (-0.431962347578785%)

BSE HC

S&P Bse Healthcare
39619.96
  -643.730000000003 (-1.59878540690136%)

BSE500

S&P Bse 500
32535.94
  -221.630000000001 (-0.676576437141097%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
11517.23
  -92.5100000000002 (-0.796830936782389%)

MSL400

S&P Bse 400 MidSmallCap
10486.84
  -95.7099999999991 (-0.904413397527049%)

ALLCAP

S&P Bse Allcap
9557.22
  48.3799999999992 (0.508789715675095%)

SML250

S&P Bse 250 SmallCap
5896.3
  -27.96 (-0.471957679102541%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-22.94%
3 Year0.5%
5 Year22.09%

Profit Growth

1 Year-29.54%
3 Year-0.42%
5 Year22.77%

ROE%

1 Year16.03%
3 Year28.55%
5 Year31.75%

ROCE %

1 Year21.27%
3 Year35.85%
5 Year38.59%

Debt/Equity

0.0188

Price to Cash Flow

84.08

Interest Cover Ratio

56.0419

CFO/PAT (5 Yr. Avg.)

0.971559048376076

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 50.10 0.00
Sep 2024 50.10 0.00
Jun 2024 50.10 0.00
Mar 2024 50.10 0.00
Dec 2023 60.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 30.5867 Cr.
  • Company has been maintaining healthy ROE of 28.5508511188353% over the past 3 years.
  • Company has been maintaining healthy ROCE of 35.8481840579725% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 56.0419.
  • The Company has been maintaining an effective average operating margins of 43.6928586629039% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 70.6698 days.
  • Company has a healthy liquidity position with current ratio of 6.4235.
  • The company has a high promoter holding of 50.1%.

 Limitations

  • The company has shown a poor profit growth of -0.415454095245549% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.501729439338128% for the Past 3 years.
  • The company is trading at a high PE of 110.83.
  • The company is trading at a high EV/EBITDA of 71.6856.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 212.82 243.52 222.09 236.06 275.39
Total Expenditure 143.76 171.38 139.05 135.05 159.93
Operating Profit 69.06 72.14 83.04 101.01 115.46
Other Income 13.97 16.87 17.95 13.43 15.18
Interest 2.15 2.29 1.6 1.47 2.6
Depreciation 11.38 15.67 12 12.29 13.44
Exceptional Items 0 0 0 0 0
Profit Before Tax 69.5 71.05 87.39 100.68 114.6
Tax 17.14 17.62 22.31 24.35 28.25
Profit After Tax 52.36 53.43 65.08 76.33 86.35
Adjusted EPS (Rs) 2.06 2.1 2.56 3 3.39

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 833.79 1009.72 1320.22 1330.08 1024.99
Total Expenditure 449 566.68 737.94 739.39 615.09
Operating Profit 384.79 443.04 582.28 590.69 409.9
Other Income 18.12 14.24 187.79 44.55 55.09
Interest 21.81 11.66 8.53 12.75 7.43
Depreciation 23.51 31.64 39.1 43.1 48.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 357.59 413.98 722.45 579.39 408.77
Tax 87.51 105.33 164.35 146.79 103.96
Net Profit 270.08 308.65 558.1 432.6 304.82
Adjusted EPS (Rs.) 10.61 12.12 21.92 16.99 11.97

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.73 25.46 25.46 25.46 25.46
Total Reserves 770.1 1039.73 1495.24 1723.92 2030.44
Borrowings 91.25 35.59 28.44 4.56 0
Other N/C liabilities 36.42 38.32 46.75 50.21 79.38
Current liabilities 319.85 321.49 346.23 298.5 203.58
Total Liabilities 1230.35 1460.59 1942.11 2102.65 2338.86
Assets
Net Block 356.74 441.16 534.19 512.03 523.54
Capital WIP 101.56 96.15 29.99 164.81 178.97
Intangible WIP 0.14 0.17 0 0 0.11
Investments 245.65 245.65 118.67 317.21 317.21
Loans & Advances 15.06 10.85 13.07 9.16 11.33
Other N/C Assets 0.2 0.16 0 0 0
Current Assets 511 666.45 1246.19 1099.44 1307.69
Total Assets 1230.35 1460.59 1942.11 2102.65 2338.86
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 357.59 413.98 722.45 579.39 408.77
Adjustment 33.35 36.48 -110.18 35.68 10.22
Changes in Assets & Liabilities 54.22 -12.19 -190.63 23.53 60.17
Tax Paid -86.41 -109.44 -151.74 -145.79 -108.52
Operating Cash Flow 358.75 328.84 269.89 492.82 370.65
Investing Cash Flow -366.65 -257.66 -90.29 -236.86 -381.58
Financing Cash Flow 8.57 -75.66 -156.48 -243.14 -13.78
Net Cash Flow 0.67 -4.49 23.12 12.81 -24.71

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 60.00 50.10 50.10 50.10 50.10
berhyanda limited 50.10 50.10 50.10 50.10 50.10
jasti property and equity... 9.90 - - - -
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 40.00 49.90 49.90 49.90 49.90
dsp value fund - - 6.06 - 4.67
goldman sachs funds - gol... - 1.11 1.16 1.19 1.09
hsbc multi cap fund - - 1.14 - 1.05
invesco india elss tax sa... - - - - 1.52
investor education and pr... - 0.14 0.14 - 0.14
jasti property and equity... - - 9.90 9.90 9.90
sbi life insurance co. lt... - - 1.10 1.91 2.85
uti-unit linked insurance... - 3.76 2.96 - 1.53
dsp healthcare fund 3.83 - - 5.40 -
hsbc small cap fund - - - 1.13 -
invesco india manufacturi... - - - 1.03 -
investor education and pr... 0.14 - - 0.14 -
tata nifty 500 multicap i... - - - 1.02 -
uti small cap fund 3.95 - - 1.89 -
dsp equity savings fund - 5.91 - - -
hsbc midcap fund 1.55 1.57 - - -
jasti property and equity... - 9.90 - - -
amansa holdings private l... 2.38 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Suven Pharma - Quaterly Results 12 Feb, 5:34 PM Suven Pharma - Quaterly Results 12 Feb, 5:34 PM Suven Pharma - Quaterly Results 12 Feb, 5:34 PM Suven Pharmaceuticals informs about investor presentation 15 Jan, 11:18 AM Suven Pharmaceuticals acquires 56% stake in NJ Bio 21 Dec, 6:01 PM Suven Pharmaceuticals to acquire controlling stake in NJ Bio 7 Dec, 5:29 PM Suven Pharmaceuticals informs about press release & investor presentation 7 Dec, 9:17 AM Suven Pharma - Quaterly Results 12 Nov, 6:25 PM Suven Pharma - Quaterly Results 12 Nov, 6:25 PM Suven Pharmaceuticals’ arm gets EIR from USFDA for manufacturing facility 9 Sep, 6:00 PM Suven Pharma - Quaterly Results 9 Aug, 3:34 PM Suven Pharma - Quaterly Results 9 Aug, 3:34 PM Suven Pharma - Quaterly Results 9 Aug, 3:34 PM Suven Pharmaceuticals informs about confirmation certificates 18 Jul, 2:30 PM USFDA completes surveillance inspection of Suven Pharmaceuticals’ arm 15 Jul, 10:12 AM Suven Pharmaceuticals informs about disclosures 19 Jun, 1:33 PM Suven Pharmaceuticals informs about disclosure 19 Jun, 12:45 PM Suven Pharmaceuticals informs about update on amalgamation 15 Jun, 3:41 PM Suven Pharma - Quaterly Results 30 May, 5:38 PM Suven Pharma - Quaterly Results 30 May, 5:38 PM Suven Pharma - Quaterly Results 30 May, 5:38 PM USFDA completes inspections at Suven Pharmaceuticals’ API, Formulations facilities 23 Feb, 5:15 PM Suven Pharma - Quaterly Results 5 Feb, 5:19 PM Suven Pharma - Quaterly Results 5 Feb, 5:19 PM Suven Pharma - Quaterly Results 5 Feb, 5:19 PM Suven Pharmaceuticals informs about disclosure 6 Dec, 2:46 PM Suven Pharmaceuticals informs about investor presentation 24 Nov, 5:24 PM Suven Pharma - Quaterly Results 9 Nov, 5:49 PM Suven Pharma - Quaterly Results 9 Nov, 5:49 PM Suven Pharmaceuticals informs about letter of offer 11 Oct, 2:50 PM Advent International completes acquisition of Suven Pharmaceuticals 30 Sep, 3:56 PM Suven Pharmaceuticals informs about transcript of conference call 14 Aug, 4:34 PM Suven Pharma - Quaterly Results 8 Aug, 4:14 PM Suven Pharma - Quaterly Results 8 Aug, 4:14 PM Suven Pharma - Quaterly Results 8 Aug, 4:14 PM Suven Pharmaceuticals informs about disclosure 12 Jun, 4:52 PM Suven Pharmaceuticals informs about earnings call transcript 2 Jun, 4:59 PM Suven Pharma - Quaterly Results 25 May, 1:41 PM Suven Pharma - Quaterly Results 25 May, 1:41 PM Suven Pharma - Quaterly Results 25 May, 1:41 PM CCI approves acquisition of up to 76.10% of voting share capital of Suven by Berhyanda 21 Apr, 10:00 AM Suven Pharmaceuticals informs about loss of share certificate 18 Mar, 12:21 PM Suven Pharma - Quaterly Results 6 Feb, 1:12 PM Suven Pharma - Quaterly Results 6 Feb, 1:12 PM Suven Pharma - Quaterly Results 6 Feb, 1:12 PM Suven Pharmaceuticals informs about conference call for investors 31 Jan, 11:40 AM Suven Pharmaceuticals informs about board meeting 30 Jan, 5:16 PM Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family 26 Dec, 9:42 AM Suven Pharmaceuticals informs about open offer 26 Dec, 9:26 AM Suven Pharmaceuticals informs about press release 26 Dec, 9:17 AM

Suven Pharma Stock Price Analysis and Quick Research Report. Is Suven Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Suven Pharma and its performance over the period of time. Suven Pharma stock price today is Rs 1226.45.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Suven Pharma cash from the operating activity was Rs 370.6473 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Suven Pharma has a Debt to Equity ratio of 0.0188 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Suven Pharma , the EPS growth was -29.539 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Suven Pharma has OPM of 39.9904799368425 % which is a good sign for profitability.
     
  • ROE: Suven Pharma have a average ROE of 16.0291 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Suven Pharma is Rs 1226.45. One can use valuation calculators of ticker to know if Suven Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Suven Pharma

Suven Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to our stock analysis page for Suven Pharmaceuticals Ltd., a leading player in the Indian Pharmaceutical Industry. As an Indian long-term stock investor, you are likely always on the lookout for valuable investment opportunities with the potential for growth over time. Ticker provides a comprehensive guide to Suven Pharmaceuticals Ltd.'s stock analysis, offering insights into its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

In addition to providing an in-depth analysis of these key strategies, we offer pre-built screening tools that help investors track the performance of the stock. Ticker also provides downloadable annual reports and quarterly results, allowing you to stay up-to-date with the company’s performance.

Through assessing the balance sheet, quarterly results, and profit and loss, Ticker’s premium features allow for fair value calculation using tools - DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. With these tools, you gain a deeper understanding of the company's financial position, enabling you to make better investment decisions.

Suven Pharmaceuticals Ltd Share Price 

The share price of Suven Pharmaceuticals Ltd. is an important metric for assessing the company's market sentiment and investor perception. Ticker provides the latest share price information and pre-built screening tools to help investors track the stock's performance. By keeping a close eye on market trends, investors can make more informed buying, selling, or holding decisions for Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd Balance Sheet 

Suven Pharmaceuticals Ltd.'s balance sheet offers a window into the company's financial position by providing valuable information on its assets, liabilities, and shareholders’ equity. Through Ticker's premium tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, investors can make fair value calculations for the company. By analyzing the balance sheet, investors can gain a better understanding of the company's relative financial health and stability, providing vital information to guide their investment strategy.

Suven Pharmaceuticals Ltd Annual Report 

The Suven Pharmaceuticals Ltd. annual report gives an in-depth analysis of the company's performance, strategy, and future plans, making it essential reading for investors. Ticker provides annual reports as downloadable files for investors to read and analyze. By studying the annual report, investors can understand the company's business prospects, assess its ability to pay dividends, and make well-informed investment decisions.

Suven Pharmaceuticals Ltd Dividend 

For investors seeking income from their investments, tracking a company's dividend history and making informed decisions accordingly is an essential step. Ticker provides information on Suven Pharmaceuticals Ltd.'s dividend payments and history. By studying dividend payouts, investors can understand the company's fiscal health and predict its ability to pay out future dividends.

Suven Pharmaceuticals Ltd Quarterly Result 

Assessing the quarterly results of Suven Pharmaceuticals Ltd. in terms of revenue, expenses, and profits is essential for long-term investors to gauge the financial performance of the company. As such, Ticker offers downloadable quarterly reports that provide an in-depth analysis of the company's financial position. By understanding the trends and developments highlighted in these reports, investors can make more informed decisions about buying, holding or selling the stock.

Suven Pharmaceuticals Ltd Stock Price 

Tracking the stock price of Suven Pharmaceuticals Ltd. is one of the crucial steps investors must take to assess how the market perceives the company's potential for growth and future prospects. Ticker provides real-time stock price information. Tracking historical stock trends through the website's pre-built screening tools is an excellent way to gain a deeper understanding of market sentiment and assist in making better-informed investment decisions.

Suven Pharmaceuticals Ltd Price Chart 

For technical analysis purposes, visual representation of the company's stock price movements is crucial. As such, Ticker offers price charts of Suven Pharmaceuticals Ltd. By studying historical trends and patterns, investors can develop trading strategies. Moreover, using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis can reinforce their investment approach.

Suven Pharmaceuticals Ltd News 

Being well-informed on the latest news and developments about Suven Pharmaceuticals Ltd. is important for investors looking to make strategic investment decisions. Ticker provides a dedicated news section, covering the latest updates and announcements related to the company. By staying up-to-date with the latest company news, investors can change their investment strategy based on new information and market trends.

Suven Pharmaceuticals Ltd ConcCall Transcripts 

Concall transcripts of Suven Pharmaceuticals Ltd. offer valuable insights into the company's management discussions, strategy, and performance. Ticker offers downloadable concall transcripts. By analyzing the transcripts, investors can keep abreast of key developments and changes, giving them the edge to make informed investment decisions.

Suven Pharmaceuticals Ltd Investor Presentations 

Studying the investor presentations of Suven Pharmaceuticals Ltd. is a smart way to understand the company’s strategy, business model, and long-term growth plans. Ticker offers downloadable investor presentations in a comprehensive format for investors, allowing them to gain a better perspective on the company's performance plans. With our fair value calculation tools, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, investors can gauge the long-term growth potential of Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd Promoters 

Promoters are key figures in Suven Pharmaceuticals Ltd.’s success, and understanding them is as critical as balancing the balance sheet. By studying the promoters' shareholding pattern and background, investors can form a better understanding of the management team's motivations, competence, and credibility. Ticker provides comprehensive information on Suven Pharmaceuticals Ltd.'s promoters to assist investors in their research.

Suven Pharmaceuticals Ltd Shareholders 

Knowing and analyzing the shareholding pattern of Suven Pharmaceuticals Ltd. is helpful in determining investor sentiment. Ticker provides information on the company's major shareholders and institutional investors. Understanding investors' interest levels can better assist and inform an individual's investment strategy.

Suven Pharmaceuticals Ltd ROCE

Return on Capital Employed (ROCE) is a key financial ratio that provides insight into the efficiency and profitability of Suven Pharmaceuticals Ltd's capital investments. This ratio helps investors understand how well the company is utilizing its capital to generate profits. You can find the ROCE data for Suven Pharmaceuticals Ltd in the financials table or the ratio section on this page.

Suven Pharmaceuticals Ltd EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a metric that reveals Suven Pharmaceuticals Ltd's operating performance and profitability before accounting for non-operating expenses. By analyzing EBITDA, investors can gauge the company's core operational earnings. To access Suven Pharmaceuticals Ltd's EBITDA data, refer to the financials table or the ratio section above.

Suven Pharmaceuticals Ltd DPS

Dividends Per Share (DPS) signifies the portion of Suven Pharmaceuticals Ltd's profits distributed to shareholders per outstanding share. This metric is crucial for income investors seeking steady dividend income. You can easily locate Suven Pharmaceuticals Ltd's DPS information in the financials table or the ratio section on this page.

Suven Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) indicates the portion of Suven Pharmaceuticals Ltd's profit allocated to each outstanding share of its common stock. Analyzing EPS helps investors evaluate the company's profitability on a per-share basis. To access Suven Pharmaceuticals Ltd's EPS data, navigate to the financials table or the ratio section provided above. 

Suven Pharmaceuticals' Equity and Liabilities Evolution

Over the years, Suven Pharmaceuticals has seen significant changes in its equity and liabilities structure, reflecting the company's evolution. The share capital has remained stable at Rs. 25.46 Cr. from March 2021 onwards, indicating no further dilution or capital raise through equity. However, a noticeable increase in total reserves, growing from Rs. 770.10 Cr. in Mar 2020 to Rs. 2,030.44 Cr. by Mar 2024, showcases the company's strong profit retention and reinvestment strategy. The reduction of borrowings to zero by Mar 2024 from Rs. 91.25 Cr. in Mar 2020 highlights the company's focus on reducing debt and improving its financial health.

Suven Pharmaceuticals' Asset Growth

Suven Pharmaceuticals' asset base has expanded significantly, with total assets increasing from Rs. 1,230.35 Cr. in Mar 2020 to Rs. 2,338.86 Cr. by Mar 2024. This growth is backed by a substantial increase in current assets, which rose to Rs. 1,307.69 Cr. by Mar 2024, indicating enhanced operational efficiency and working capital management. The consistent investment in Net Block and Capital WIP illustrates the company's commitment to growth and capacity expansion.

Expansion and Reduction in Suven Pharmaceuticals' Liabilities

A notable reduction in borrowings and a well-managed liability structure demonstrate Suven Pharmaceuticals' prudent financial management. The company's liabilities have been strategically structured, with a significant paydown in borrowings and an appropriate handling of current liabilities, which decreased to Rs. 203.58 Cr. by Mar 2024. This strategic financial maneuvering supports Suven Pharmaceuticals' growth trajectory while ensuring financial stability.

This data is an analysis for the Standalone Balance sheet of the company.

Engaging with Suven Pharmaceuticals' financial health could offer insights into potential market movements, beneficial for investors looking into the pharma sector or tracking NSE and BSE indices for informed investment decisions.

Read More
X